Comparison of Efficacy of Oral Azithromycin Versus Oral Chloroquine in the Treatment of Cutaneous Leishmaniasis

Mahevish Bhutto; Mohammad Riaz Khan

doi:10.70749/ijbr.v3i4.834

Authors

Mahevish Bhutto Department of Dermatology, PIMS Hospital, Islamabad, Pakistan.
Mohammad Riaz Khan Department of Dermatology, PIMS Hospital, Islamabad, Pakistan.

DOI:

https://doi.org/10.70749/ijbr.v3i4.834

Keywords:

Cutaneous leishmaniasis, Chloroquine, Azithromycin, Treatment efficacy

Abstract

Background: Cutaneous leishmaniasis is a parasitic disease-causing significant morbidity, particularly in endemic regions. Effective and accessible treatments are crucial, especially in resource-limited settings. While antimonials remain the standard, oral chloroquine and azithromycin have emerged as potential alternatives, though their comparative efficacy remains understudied. Objective: To compare the efficacy of oral azithromycin and oral chloroquine in the treatment of cutaneous Leishmaniasis. Study Design: Randomized controlled trial. Duration and Place of Study: The study was conducted from December 2024 to February 2025 at the Dermatology Department of the Pakistan Institute of Medical Sciences (PIMS), Islamabad. Methodology: Sixty patients with confirmed CL were randomized into two groups: Group A received oral chloroquine (250 mg twice daily) and Group B received oral azithromycin (250 mg twice daily) for six weeks. Lesion characteristics, including size, induration and healing were assessed fortnightly. Efficacy was defined as complete lesion healing with or without scarring, confirmed by reduced lesion size and absence of amastigotes on rebiopsy. Results: The mean age of participants was 36.82 ± 10.54 years, with 63.3% males and 36.7% females. Lesions were predominantly on hands and arms (73.3% in Group A, 53.3% in Group B). Chloroquine demonstrated significantly higher efficacy (90%) compared to azithromycin (60%) (p=0.015). Conclusion: Our study confirms that oral chloroquine is highly effective for cutaneous leishmaniasis, outperforming azithromycin. Chloroquine showed consistent efficacy across age, gender and lesion locations, particularly for extremity lesions and shorter disease duration. Azithromycin had moderate overall efficacy but was significantly less effective in females and body lesions.

Downloads

Download data is not yet available.

References

de Vries HJC, Schallig HD. Cutaneous leishmaniasis: a 2022 updated narrative review into diagnosis and management developments. Am J Clin Dermatol. 2022;23(6):823-40. https://doi.org/10.1007/s40257-022-00726-8.

Madusanka RK, Silva H, Karunaweera ND. Treatment of cutaneous leishmaniasis and insights into species-specific responses: a narrative review. Infect Dis Ther. 2022;11(2):695-711. https://doi.org/10.1007/s40121-022-00602-2.

Kayani B, Sadiq S, Rashid HB, Ahmed N, Mahmood A, Khaliq MS, et al. Cutaneous leishmaniasis in Pakistan: a neglected disease needing one health strategy. BMC Infect Dis. 2021;21(1):622. https://doi.org/10.1186/s12879-021-06327-w.

Costa-da-Silva AC, Nascimento DO, Ferreira JRM, Guimarães-Pinto K, Freire-de-Lima L, Morrot A, et al. Immune responses in leishmaniasis: an overview. Trop Med Infect Dis. 2022;7(4):54. https://doi.org/10.3390/tropicalmed7040054.

Piyasiri SB, Dewasurendra R, Samaranayake N, Karunaweera N. Diagnostic tools for cutaneous leishmaniasis caused by Leishmania donovani: a narrative review. Diagnostics (Basel). 2023;13(18):2989. https://doi.org/10.3390/diagnostics13182989.

Garza-Tovar TF, Sacriste-Hernández MI, Juárez-Durán ER, Arenas R. An overview of the treatment of cutaneous leishmaniasis. Fac Rev. 2020;9:28. https://doi.org/10.12703/r/9-28.

Solomon M, Ollech A, Pavlotsky F, Barzilai A, Schwartz E, Baum S, et al. Comparison of intralesional sodium stibogluconate versus intralesional meglumine antimoniate for the treatment of Leishmania major cutaneous leishmaniasis. Acta Derm Venereol. 2024;104:adv35089. https://doi.org/10.2340/actadv.v104.35089.

Ullah O, Rizwan M, Raza N, Zulfiqar S, Akbar N, Ullah H. Comparative efficacy of intralesional chloroquine with intralesional meglumine antimoniate in the treatment of cutaneous leishmaniasis. Cureus. 2024;16(3):e56785. https://doi.org/10.7759/cureus.56785.

Abtahi-Naeini B, Hadian S, Sokhanvari F, Hariri A, Varshosaz J, Shahmoradi Z, et al. Effect of adjunctive topical liposomal azithromycin on systemic azithromycin on old world cutaneous leishmaniasis: a pilot clinical study. Iran J Pharm Res. 2021;20(2):383-9. https://doi.org/10.22037/ijpr.2020.113710.14445.

Zhang H, Yan R, Liu Y, Yu M, He Z, Xiao J, et al. Progress in antileishmanial drugs: mechanisms, challenges, and prospects. PLoS Negl Trop Dis. 2025;19(1):e0012735. https://doi.org/10.1371/journal.pntd.0012735.

Memariani H, Memariani M, Ghasemian A. Quercetin as a promising antiprotozoan phytochemical: current knowledge and future research avenues. Biomed Res Int. 2024;2024:7632408. https://doi.org/10.1155/2024/7632408.

Siqueira-Neto JL, Wicht KJ, Chibale K, Burrows JN, Fidock DA, Winzeler EA. Antimalarial drug discovery: progress and approaches. Nat Rev Drug Discov. 2023;22(10):807-26. https://doi.org/10.1038/s41573-023-00772-9.

Pillat MM, Krüger A, Guimarães LMF, Lameu C, de Souza EE, Wrenger C, et al. Insights in chloroquine action: perspectives and implications in malaria and COVID-19. Cytometry A. 2020;97(9):872-81. https://doi.org/10.1002/cyto.a.24190.

Heras-Mosteiro J, Monge-Maillo B, Pinart M, Lopez Pereira P, Reveiz L, Garcia-Carrasco E, et al. Interventions for old world cutaneous leishmaniasis. Cochrane Database Syst Rev. 2017;12(12):CD005067. https://doi.org/10.1002/14651858.CD005067.pub5

Herrera L, Llanes A, Álvarez J, Degracia K, Restrepo CM, Rivera R, et al. Antileishmanial activity of a new chloroquine analog in an animal model of Leishmania panamensis infection. Int J Parasitol Drugs Drug Resist. 2020;14:56-61. https://doi.org/10.1016/j.ijpddr.2020.08.002.

Malik F, Hanif MM, Mustafa G. Comparing the efficacy of oral chloroquine versus oral tetracycline in the treatment of cutaneous leishmaniasis. J Coll Physicians Surg Pak. 2019;29(5):403-5. https://doi.org/10.29271/jcpsp.2019.05.403

Shahzad MK, Tahir R, Khan S, Memon Q, Shafquat H, Memon GM, et al. Efficacy of oral azithromycin for the treatment of cutaneous leishmaniasis. Pak J Med Health Sci. 2020;14(4):1962-6.

Farooq M, Farooq MS, Bari AU, Malik TM. Comparison of oral chloroquine with systemic meglumine antimoniate in treatment of cutaneous leishmaniasis. Pak Armed Forces Med J. 2021;71(1):139-44. https://doi.org/10.51253/pafmj.v71i1.3187

Paracha M, Wasim M, Noor SM, Khan AQ, Ahmad I. Comparing intramuscular meglumine antimoniate with oral chloroquine in the treatment of cutaneous leishmaniasis: a randomized controlled trail. J Pak Assoc Dermatol. 2024;34(3):599-605.

Seyyed Mohammad A, Leila A. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. J Gorgan Univ Med Sci. 2008;10(4):1-5.

Prata A, Silva-Vergara ML, Costa L, Rocha A, Krolewiecki A, Silva JC, et al. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Rev Soc Bras Med Trop. 2003;36(1):65-9. https://doi.org/10.1590/s0037-86822003000100010

Hanif MM, Akram K, Mustafa G. Intralesional versus oral chloroquine in cutaneous leishmaniasis: comparison of outcome, duration of treatment and total dose of drug. J Coll Physicians Surg Pak. 2016;26(4):260-2.